Diversified Trust Co. Buys 1,775 Shares of Elevance Health, Inc. $ELV

Diversified Trust Co. boosted its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,926 shares of the company’s stock after acquiring an additional 1,775 shares during the quarter. Diversified Trust Co.’s holdings in Elevance Health were worth $12,594,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ELV. Evergreen Wealth Management LLC boosted its holdings in shares of Elevance Health by 33.5% in the 3rd quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock worth $5,584,000 after acquiring an additional 4,336 shares in the last quarter. Blume Capital Management Inc. grew its position in Elevance Health by 236.7% during the 3rd quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock worth $1,986,000 after acquiring an additional 4,320 shares during the last quarter. Canoe Financial LP increased its holdings in Elevance Health by 18.1% during the 3rd quarter. Canoe Financial LP now owns 389,399 shares of the company’s stock valued at $125,823,000 after purchasing an additional 59,743 shares in the last quarter. Synergy Asset Management LLC raised its position in Elevance Health by 100.0% in the 3rd quarter. Synergy Asset Management LLC now owns 104,334 shares of the company’s stock valued at $33,712,000 after purchasing an additional 52,167 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in Elevance Health by 31.1% in the 3rd quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock valued at $149,182,000 after purchasing an additional 109,462 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Trading Down 0.7%

Shares of ELV opened at $289.58 on Tuesday. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75. The firm has a market capitalization of $63.91 billion, a PE ratio of 11.53, a price-to-earnings-growth ratio of 1.60 and a beta of 0.51. The stock’s fifty day simple moving average is $328.88 and its 200-day simple moving average is $333.44.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company’s revenue was up 9.6% on a year-over-year basis. During the same period last year, the company earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be given a dividend of $1.72 per share. The ex-dividend date is Tuesday, March 10th. This represents a $6.88 annualized dividend and a dividend yield of 2.4%. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is presently 27.39%.

Analyst Ratings Changes

ELV has been the topic of several research analyst reports. Morgan Stanley decreased their target price on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 17th. Robert W. Baird lifted their price target on Elevance Health from $297.00 to $340.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $332.00 price objective on shares of Elevance Health in a report on Thursday, January 29th. Wells Fargo & Company lowered their price objective on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research report on Friday, January 30th. Finally, Royal Bank Of Canada downgraded shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a research note on Tuesday, February 3rd. Twelve investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $387.40.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.